Skip to Content
Søg Menu
Vi dækker

ASCO | American Society of Clinical Oncology

ASCO 2025

Jeanne Tie

The randomized DYNAMIC Trial: ctDNA-guided approach towards adjuvant chemotherapy

/ Jeanne Tie
ASCO22Colorektalcancer Play the Video
David Cella, Dr

HRQoL as Prognostic Value for Overall Survival in Patients with RCC Receiving ICIs

/ David Cella
ASCO22Nyrecancer Play the Video

ASCO 2024

Thorgerdur Palsdottir

The Capio Model for Prostate Cancer Diagnostics

/ Thorgerdur Palsdottir
ASCO24Prostatacancer Play the Video

Joaquim Bellmunt

First-Line Maintenance Therapy with Avelumab Show Significantly Prolonged OS and PFS in Patients with Advanced Urothelial Cancer with Low Tumor Burden

/ Joaquim Bellmunt
ASCO24Blærecancer Play the Video
Cathy Burton

Paradigm Changes in Hodgkin’s Lymphoma Treatments

/ Cathy Burton
ASCO24Hodgkins lymfomLymfom Play the Video
Oluf Dimitri Røe

ASCO24: Very Exciting Steps for Early Diagnosis and Lung Cancer

/ Oluf Dimitri Røe
ASCO24Lungecancer Play the Video

Trastuzumab Deruxtecan Significantly Improves Progression-Free Survival in Breast Cancer Patients Previously Treated with Endocrine Therapy

/ Sofie Pohl
ASCO24
Oluf Dimitri Røe

Oluf Dimitri Røe: ASCO Is the Cradle of Oncology

/ Oluf Dimitri Røe
ASCO24 Play the Video

Novel Agent Increases PFS for Patients with endocrine-resistant HR+/HER2- metastatic breast cancer

/ BestPractice Nordic
HER2ASCO22Brystcancer
Hent flere

ASCO 2023

Highlights fra ASCO 2023: Nye indsigter i luminal brystkræft

/ Bent Ejlertsen
ASCO23Brystcancer
Oluf Dimitri Røe

Can We Predict Bladder Cancer Using the HUNT Model?

/ Oluf Dimitri Røe
ASCO23Blærecancer Play the Video
Stine Bakkensen Bruun

Circulating Methylated-HOXA9 Tumor DNA as a Biomarker in Recurrent Breast Cancer

/ Stine Bakkensen Bruun
ASCO23Brystcancer Play the Video
Bent Ejlertsen

Hvad var nyt på ASCO23 inden for brystcancer?

/ Bent Ejlertsen
ASCO23 Play the Video
Lars Henrik Jensen

Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer Does Not Change OS

/ Lars Henrik Jensen
ASCO23Tarmcancer Play the Video

Significant PFS Benefit for the Nivolumab + Relatlimab Combination for Patients with Unresectable or Metastatic Melanoma

/ BestPractice Nordic
ASCO23Melanom
Hent flere

ASCO 2022

Ibrutinib added to Standard-of-Care Therapy improves PFS by 50% for Older Patients with Newly Diagnosed Mantle Cell Lymphoma

/ BestPractice Nordic
ASCO22Lymfom

Health-related quality of life is associated with clinical outcomes in patients with advanced renal cell carcinoma

/ BestPractice Nordic
ASCO22Nyrecancer

Nivolumab in combination with relatlimab significantly improved PFS in patients with previously untreated metastatic or unresectable melanoma

/ BestPractice Nordic
ASCO22Hudcancer

Se tidligere dækning af ASCO 2021 og 2020

Potentiel førstelinjebehandling ved avanceret renalcellecarcinom

/ BestPractice Nordic
ASCO21Nyrecancer
Woman with cancer looking at x-ray

Neoadjuvant nivolumab + kemoterapi forbedrer komplet patologisk responsrate og forkorter operationstid uanset stadie af NSCLC

/ BestPractice Nordic
NSCLCLungecancerASCO21
Man at the doctor

Radioligand reducerer risikoen for progression og død for patienter med metastatisk kastrationsresistent prostatacancer

/ BestPractice Nordic
ASCO21Prostatacancer
Self Diagnosis Of Early Breast Cancer

Olaparib kan ændre klinisk praksis i adjuverende behandling af brystcancer

/ BestPractice Nordic
BrystcancerASCO21
Tværsnit af en nyre

KEYNOTE-564 viser lovende resultater for adjuverende behandling med pembrolizumab til højrisiko nyrekræft

/ BestPractice Nordic
ASCO21Nyrecancer
Lung Cancer

Bliver atezolizumab ny standard for adjuverende behandling af patienter med NSCLC?

/ BestPractice Nordic
NSCLCLungecancerASCO21
Mere

Back to top